Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159120 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71
Last updated 2008-01-30
Summary
After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year. Under both conditions prodrome based early intervention take place.
Conditions
- Schizophrenia
- Psychoses
Interventions
- OTHER
-
maintained antipsychotic treatment vs. stepwise drug discontinuation
maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Sponsors & Collaborators
-
German Federal Ministry of Education and Research
collaborator OTHER_GOV -
German Research Network On Schizophrenia
collaborator NETWORK -
Janssen-Cilag Ltd.
collaborator INDUSTRY -
University of Bonn
collaborator OTHER -
Humboldt-Universität zu Berlin
collaborator OTHER -
Ludwig-Maximilians - University of Munich
collaborator OTHER -
University of Göttingen
collaborator OTHER -
University of Cologne
collaborator OTHER -
Mainz University
collaborator OTHER -
University Hospital Tuebingen
collaborator OTHER -
Universität Duisburg-Essen
collaborator OTHER -
University of Mannheim
collaborator OTHER -
University of Jena
collaborator OTHER -
Martin-Luther-Universität Halle-Wittenberg
collaborator OTHER -
RWTH Aachen University
collaborator OTHER -
University of Wuerzburg
collaborator OTHER -
Heinrich-Heine University, Duesseldorf
lead OTHER
Principal Investigators
-
Wolfgang Gaebel, Professor · Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University of Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstraße 2, 40629 Düsseldorf, Germany
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-11-30
- Primary Completion
- 2006-06-30
- Completion
- 2006-06-30
Countries
- Germany
Study Locations
More Related Trials
-
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
NCT00253110 ·Status: COMPLETED ·Phase: PHASE4
-
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
NCT03090490 ·Status: UNKNOWN ·Phase: NA
-
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
NCT00378092 ·Status: COMPLETED ·Phase: PHASE4
-
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00215579 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
NCT00660595 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment for First-Episode Schizophrenia
NCT00000374 ·Status: COMPLETED ·Phase: PHASE4
-
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
NCT00216671 ·Status: COMPLETED ·Phase: PHASE4
-
Risperidone Maintenance Treatment in Schizophrenia
NCT00848432 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
NCT00249132 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
NCT07152184 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
NCT00249119 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Seroquel in First Episode Schizophrenia
NCT00254241 ·Status: COMPLETED ·Phase: PHASE4
-
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
NCT03248180 ·Status: UNKNOWN
-
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
NCT02431702 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
NCT00297388 ·Status: COMPLETED ·Phase: PHASE3
-
Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate
NCT02532842 ·Status: COMPLETED
-
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
NCT01081769 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
NCT02532491 ·Status: UNKNOWN ·Phase: PHASE4
-
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
NCT06128408 ·Status: NOT_YET_RECRUITING
-
Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant
NCT00174577 ·Status: UNKNOWN ·Phase: PHASE3
-
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
NCT05473741 ·Status: COMPLETED
-
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
NCT00237861 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
NCT02713282 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
NCT01009047 ·Status: COMPLETED ·Phase: PHASE3